iRhythm Technologies Study Shows 14-Day Monitoring Detects Nearly 3x More High-Risk Nonsustained Ventricular Tachycardia Episodes In Hypertrophic Cardiomyopathy Patients Compared To 48-Hour Monitoring; Findings Support Improved Risk Assessment For Sudden Cardiac Death
Portfolio Pulse from Benzinga Newsdesk
iRhythm Technologies' study reveals that 14-day monitoring detects nearly three times more high-risk nonsustained ventricular tachycardia episodes in hypertrophic cardiomyopathy patients compared to 48-hour monitoring. This supports improved risk assessment for sudden cardiac death.
October 28, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
iRhythm Technologies' study shows significant improvement in detecting high-risk cardiac episodes with 14-day monitoring, potentially enhancing their product's value and market position.
The study highlights a significant improvement in iRhythm's monitoring technology, which could lead to increased adoption and sales, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90